HIV infection and the fronto-striatal system: A systematic review and meta-analysis of fMRI studies

AIDS

Volumn 28, Issue 6, 2014, Pages 803-811

  Du Plessis, Stéfan ^a   Vink, Matthijs ^b   Joska, John A ^e   Koutsilieri, Eleni ^c   Stein, Dan J ^d,e   Emsley, Robin ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Medical Research Council (Unit on Anxiety and Stress Disorders)   (Germany)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

AIDS; Brain; Cognition; Dementia; FMRI; HAART; HIV

Indexed keywords

BRAIN; BRAIN DYSFUNCTION; BRAIN FUNCTION; BRAIN INJURY; CAUDATE NUCLEUS; CD4 LYMPHOCYTE COUNT; COGNITIVE DEFECT; COMORBIDITY; DISEASE COURSE; DOPAMINERGIC TRANSMISSION; FRONTO STRIATAL PARIETAL NETWORK; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEPATITIS C; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFERIOR FRONTAL GYRUS; INSULA; METHAMPHETAMINE DEPENDENCE; NEUROSYPHILIS; OCCIPITAL CORTEX; PARIETAL CORTEX; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SUBSTANCE ABUSE; SUBSTANCE USE; SUPPLEMENTARY MOTOR AREA; SYSTEMATIC REVIEW; THALAMUS; THERAPY EFFECT; VIRUS TRANSMISSION; WORKING MEMORY;

AIDS DEMENTIA COMPLEX; FRONTAL LOBE; HIV INFECTIONS; HUMANS; MAGNETIC RESONANCE IMAGING; VISUAL CORTEX;

EID: 84898013039     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000151     Document Type: Review

References (73)

1. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology 2010; 75:2087-2095.
2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV associated neurocognitive disorders. Neurology 2007; 69:1789-1799.
3. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257-260.
4. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8:136-142.
5. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004; 157:3-10.
6. Bonnet F,Amieva H,Marquant F, Bernard C, Bruyand M,Dauchy F-A, et al. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS 2013; 27:391-400.
7. MarcotteTD, Ghate M, Deutsch R, Letendre S,Meyer R,Godbole S, et al. Earlier initiation of ART results in better neurocognitive functioning. 19th Conference on Retroviruses and Opportunistic Infections. 2012. http://www.retroconference.org/2012b/Abstracts/44698.htm [Accessed 24 May 2013].
8. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10:317-331.
9. McGuire D. CSF biomarkers in HIV dementia: through a glass darkly. Neurology 2009; 73:1942-1944.
10. Logothetis NK. What we can do and what we cannot do with fMRI. Nature 2008; 453:869-878.
11. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986; 19:517-524.
12. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R. Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 1991; 82:39-44.
13. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986; 19:525-535.
14. Cornford ME, Holden JK, Boyd MC, Berry K, Vinters HV. Neuropathology of the acquired immune deficiency syndrome (AIDS): report of 39 autopsies from Vancouver, British Columbia. Can J Neurol Sci 1992; 19:442-452.
15. Agrawal L, Louboutin J-P, Marusich E, Reyes BAS, Van Bockstaele EJ, Strayer DS. Dopaminergic neurotoxicity of HIV-1 gp120: reactive oxygen species as signaling intermediates. Brain Res 2010; 1306:116-130.
16. Purohit V, Rapaka R, Shurtleff D. Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 2011; 44:102-110.
17. Scheller C, Sopper S, Jenuwein M, Neuen-Jacob E, Tatschner T, Grünblatt E, et al. Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. J Neurochem 2005; 95:377-387.
18. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 1990; 87:9868-9872.
19. Cole D, Smith SM, Beckmann CF. Advances and pitfalls in the analysis and interpretation of resting-state FMRI data. Front Syst Neurosci 2010:1-15.
20. Detre JA, Wang J, Wang Z, Rao H. Arterial spin-labeled perfusion MRI in basic and clinical neuroscience. Curr Opin Neurol 2009; 22:348-355.
21. Chang L, Ernst T, Leonido-Yee M, Speck O. Perfusion MRI detects rCBF abnormalities in early stages of HIV-cognitive motor complex. Neurology 2000; 54:389-396.
22. Tracey I, Hamberg LM, Guimaraes AR, Hunter G, Chang I, Navia BA, et al. Increased cerebral blood volume in HIV positive patients detected by functional MRI. Neurology 1998; 50:1821-1826.
23. Ernst T, Chang L, Jovicich J, Ames N, Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 2002; 59:1343-1349.
24. Holt JL, Kraft-Terry SD, Chang L. Neuroimaging studies of the aging HIV-1-infected brain. J Neurovirol 2012; 18:291-302.
25. Tucker KA, Robertson KR, Lin W, Smith JK, An H, Chen Y, et al. Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol 2004; 157:153-162.
26. Paul R, Cohen R, Navia B, Tashima K. Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci Biobehav Rev 2002; 26:353-359.
27. Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Greenberg RN, Berger Jr. Neuroimaging correlates of HIVassociated BBB compromise. JNeuroimmunol 2004; 157:140-146.
28. Turkeltaub PE, Eickhoff SB, Laird AR, Fox M, Wiener M, Fox P. Minimizing within-experiment and within-group effects in activation likelihood estimation meta-analyses. Hum Brain Mapp 2011; 33:1-13.
29. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA Statement. Open Med 2009; 3:e123-e130.
30. Eickhoff SB, Laird AR, Grefkes C, Wang LE, Zilles K, Fox PT. Coordinate-based activation likelihood estimation meta-analysis of neuroimaging data: a random-effects approach based on empirical estimates of spatial uncertainty. Hum Brain Mapp 2009; 30:2907-2926.
31. Eickhoff SB, Bzdok D, Laird AR, Kurth F, Fox PT. Activation likelihood estimation meta-analysis revisited. NeuroImage 2012; 59:2349-2361.
32. Evans AC, Kamber M, Collins DL, MacDonald D. An MRI-based probabilistic atlas of neuroanatomy, vol. 264. United States: Springer; 1994. pp. 263-274.
33. Chang L, Speck O, Miller EN, Braun J, Jovicich J, Koch C, et al. Neural correlates of attention and working memory deficits in HIV patients. Neurology 2001; 57:1001-1007.
34. Chang L, Tomasi D, Yakupov R, Lozar C, Arnold S, Caparelli E, et al. Adaptation of the attention network in human immunodeficiency virus brain injury. Ann Neurol 2004; 56:259-272.
35. Ances BM, Roc AC, Wang J, Korczykowski M, Okawa J, Stern J, et al. Caudate blood flow and volume are reduced in HIVR neurocognitively impaired patients. Neurology 2006; 66:862-866.
36. Castelo JMB, Sherman SJ, Courtney MG, Melrose RJ, Stern CE. Altered hippocampal-prefrontal activation in HIV patients during episodic memory encoding. Neurology 2006; 66:1688-1695.
37. Chang L, Yakupov R, Nakama H, Stokes B, Ernst T. Antiretroviral treatment is associated with increased attentional loaddependent brain activation in HIV patients. J Neuroimmune Pharmacol 2007; 3:95-104.
38. Juengst SB, Aizenstein HJ, Figurski J, Lopez OL, Becker JT. Alterations in the hemodynamic response function in cognitively impaired HIV/AIDS subjects. J Neurosci Methods 2007; 163:208-212.
39. Ances BM, Clifford DB. HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Curr Neurol Neurosci Rep 2008; 8:455-461.
40. Melrose RJ, Tinaz S, Castelo JMB, Courtney MG, Stern CE. Compromised fronto-striatal functioning in HIV: an fMRI investigation of semantic event sequencing. Behav Brain Res 2008; 188:337-347.
41. Ances BM, Sisti D, Vaida F, Liang CL, Leontiev O, Perthen JE, et al. Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 2009; 73:702-708.
42. Maki PM, Cohen MH, Weber K, Little DM, Fornelli D, Rubin LH, et al. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women: a preliminary study. Neurology 2009; 72:1661-1668.
43. Ances BM, Vaida F, Yeh MJ, Liang CL, Buxton RB, Letendre S, et al. HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis 2010; 201:336-340.
44. Ances BM, Roc AC, Korczykowski M, Wolf RL, Kolson DL. Combination antiretroviral therapy modulates the blood oxygen level-dependent amplitude in human immunodeficiency virus-seropositive patients. J Neurovirol 2008; 14:418-424.
45. Ances B, Vaida F, Ellis R, Buxton R. Test-retest stability of calibrated BOLD-fMRI in HIVS and HIVR subjects. Neuro-Image 2011; 54:2156-2162.
46. Meade CS, Lowen SB, MacLean RR, Key MD, Lukas SE. fMRI brain activation during a delay discounting task in HIV-positive adults with and without cocaine dependence. Psychiatry Res: Neuroimaging 2011; 192:167-175.
47. Qiu W, Yan B, Li J, Tong L, Wang L, Shi D. A resting-state fMRI study of patients with HIV infection based on regional homogeneity method. Shanghai: Institute of Electrical and Electronics Engineers (IEEE and partners); 2011. pp. 997-1000.
48. Schweinsburg BC, Scott JC, Schweinsburg AD, Jacobus J, Theilmann RJ, Frank LR, et al. Altered prefronto-striato-parietal network response to mental rotation in HIV. J Neurovirol 2012; 18:74-79.
49. Ernst T, Yakupov R, Nakama H, Crocket G, Cole M, Watters M, et al. Declined neural efficiency in cognitively stable human immunodeficiency virus patients. Ann Neurol 2009; 65:316-325.
50. Ernst T, Chang L, Arnold S. Increased glial metabolites predict increased working memory network activation in HIV brain injury. NeuroImage 2003; 19:1686-1693.
51. Chang L, Alicata D, Ernst T, Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007; 102:16-32.
52. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med 2012; 18:182-192.
53. Goldman-Rakic PS. Comprehensive physiology. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2011doi:10.1002/cphy.cp010509.
54. Zald DH. Orbital versus dorsolateral prefrontal cortex: anatomical insights into content versus process differentiation models of the prefrontal cortex. Ann N Y Acad Sci 2007; 1121:395-406.
55. Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry 2008; 20:33-47.
56. Anthony IC, Bell PJE. The neuropathology of HIV/AIDS. Int Rev Psychiatry 2008; 20:15-24.
57. Glass JD, Fedor H, Wesselingh SL, Mcarthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995; 38:755-762.
58. Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 1996; 50:381-425.
59. Czub S, Koutsilieri E, Sopper S, Czub M, Stahl-Hennig C, Mü ller JG, et al. Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol 2001; 101:85-91.
60. Koutsilieri E, Sopper S, Scheller C, Meulen ter V, Riederer P. Involvement of dopamine in the progression of AIDS Dementia Complex. J Neural Transm 2002; 109:399-410.
61. Koutsilieri E, Sopper S, Scheller C, Meulen ter V, Riederer P. Parkinsonism in HIV dementia. J Neural Transm 2002; 109:767-775.
62. Koutsilieri E, Scheller C, Sopper S, Meulen ter V, Riederer P. The pathogenesis of HIV-induced dementia. Mech Ageing Dev 2002; 123:1047-1053.
63. Scheller C, Sopper S, Jassoy C, Meulen ter V, Riederer P, Koutsilieri E. Dopamine activates HIV in chronically infected T lymphoblasts. J Neural Transm 2000; 107:1483-1489.
64. Koutsilieri E, Gö tz ME, Sopper S, Stahl-Hennig C, Czub M, Meulen ter V, et al. Monoamine metabolite levels in CSF of SIVinfected rhesus monkeys (Macaca mulatta). Neuroreport 1997; 8:3833-3836.
65. Kumar AM, Fernandez JB, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL, et al. Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 2009; 15:257-274.
66. Rabkin JG, McElhiney MC, Ferrando SJ. Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS 2004; 18 (Suppl 1):S43-S48.
67. Nath A, Maragos WF, Avison MJ, Schmitt FA, Berger Jr. Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol 2001; 7:66-71.
68. Volkow ND, Wang GJ, Tomasi D, Baler RD. Unbalanced neuronal circuits in addiction. Curr Opin Neurobiol 2013; 23:639-648.
69. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, Mcarthur J. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 2008; 20:25-31.
70. Nath A. Human immunodeficiency virus-associated neurocognitive disorder. Ann N Y Acad Sci 2010; 1187:122-128.
71. Ances BM, Vaida F, Cherner M, Yeh MJ, Liang CL, Gardner C, et al. HIV and chronic methamphetamine dependence affect cerebral blood flow. J Neuroimmune Pharmacol 2011; 6:409-419.
72. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199-206.
73. Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004; 32:33-46.